Sipuleucel-T is an autologous cellular immunotherapy approved by the US Food and Drug Administration for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. Its mechanism of action is based on stimulation of the patient's own immune system to target prostate cancer. Peripheral blood mononuclear cells, including antigen-presenting cells and T cells, are obtained from patients via leukapheresis and treated ex vivo with PA2024, a fusion protein consisting of prostatic acid phosphatase/granulocyte-macrophage colony-stimulating factor antigen.
Methods
Data relating to the potential pharmacodynamic biomarkers associated with sipuleucel-T activity are reviewed, as well as considerations for patient selection and for sequencing sipuleucel-T with other prostate cancer treatments. Possible directions for future development are also discussed, including treatment of less advanced prostate cancer populations, combination treatment, and immune modulation.
Results
Data from three randomized, double-blind, placebo-controlled phase III clinical trials of sipuleucel-T in patients with metastatic castration-rresistant prostate cancer have shown improvement in overall survival vs control. Here, we review its developing role in prostate cancer therapy and future directions for development.
Conclusions
There is potential to build on sipuleucel-T to further advance immunotherapy of prostate cancer.
References
1.
SiegelR., NaishadhamD., JemalA.. Cancer statistics, 2012.CA Cancer J Clin.2012; 62(1): 10–29.
2.
de BonoJ.S., LogothetisC.J., MolinaA.. Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med.2011; 364(21): 1995–2005.
3.
de BonoJ.S., OudardS., OzgurogluM.. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.Lancet.2010; 376(9747): 1147–1154.
4.
FizaziK., CarducciM., SmithM.. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.Lancet.2011; 377(9768): 813–822.
5.
ParkerC., HeinrichD., O'SullivanJ.M.. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.J Clin Oncol (ASCO Genitourinary Cancers Symposium Annual Abstracts).2012; 30(suppl 5): 8.
6.
ScherH.I., FizaziK., SaadF.. Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med.2012; 367(13): 1187–1197.
7.
Described in the Exelixis website 11/18/2010 press release (http://exelixis.com/investors-media/press-releases), in reference to SmithD.C., SpiraA., De GrèveJ.. Phase 2 study of XL184 in a cohort of patients with castration resistant prostate cancer (CRPC) and measurable soft-tissue disease. Presented at the 22nd Annual EORTC- NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; November 16-19, 2010; Berlin, Germany.Eur J Cancer.2010; 8(7 suppl): 129. Poster 406.
8.
KantoffP.W., SchuetzT.J., BlumensteinB.A.. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.J Clin Oncol.2010; 28(7): 1099–1105.
9.
HodiF.S., O'DayS.J., McDermottD.F.. Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med.2010; 363(8): 711–723.
10.
HiganoC.S., SchellhammerP.F., SmallE.J.. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.Cancer.2009; 115(16): 3670–3679.
11.
HainesA.M., LarkinS.E., RichardsonA.P.. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry.Br J Cancer.1989; 60(6): 887–892.
12.
ValoneF.H., SmallE., MacKenzieM.. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.Cancer J.2001; 7(suppl 2): S53–S61.
13.
LausR., YangD.M., RueggC.L.. Dendritic cell immunotherapy of prostate cancer: preclinical models and early clinical experience.Cancer Res Ther Cont.2001; 11: 1–10.
14.
SheikhN.A., JonesL.A.. CD54 is a surrogate marker of antigen presenting cell activation.Cancer Immunol Immunother.2008; 57(9): 1381–1390.
DrakeC.G.. Prostate cancer as a model for tumour immunotherapy.Nat Rev Immunol.2010; 10(8): 580–593.
17.
ShengK.C., WrightM.D., ApostolopoulosV.. Inflammatory mediators hold the key to dendritic cell suppression and tumor progression.Curr Med Chem.2011; 18(36): 5507–5518.
18.
SatoT., TeraiM., TamuraY.. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.Immunol Res.2011; 51(2-3): 170–182.
19.
NagarajS., SchrumA.G., ChoH.I.. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.J Immunol.2010; 184(6): 3106–3116.
20.
KusmartsevS., GabrilovichD.I.. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer.Cancer Metastasis Rev.2006; 25(3): 323–331.
21.
PoschkeI., MaoY., AdamsonL.. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.Cancer Immunol Immunother.2012; 61(6): 827–838.
22.
BurchP.A., BreenJ.K., BucknerJ.C.. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.Clin Cancer Res.2000; 6(6): 2175–2182.
SheikhN.A., PetrylakD., KantoffP.W.. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.Cancer Immunol Immunother.2012 Aug 3. Epub ahead of print.
25.
SmallE.J., SchellhammerP.F., HiganoC.S.. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.J Clin Oncol.2006; 24(19): 3089–3094.
26.
FrohlichM.W.. Sipuleucel-T for the treatment of advanced prostate cancer.Semin Oncol.2012; 39(3): 245–252.
27.
GomellaL.G., NabhanC., WhitmoreJ.B.. Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase III studies.J Clin Oncol (ASCO Annual Meeting Abstracts).2011; 29(suppl): 4534.
28.
HallS.J., KlotzL., PantuckA.J.. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.J Urol.2011; 186(3): 877–881.
HuberM.L., HaynesL., ParkerC.. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.J Natl Cancer Inst.2012; 104(4): 273–279.
31.
GulleyJ.L., LeitmanS.F., DahutW.. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.J Natl Cancer Inst.2012; 104(14): 1106.
32.
DrakeC.G.. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.J Natl Cancer Inst.2012; 104(18): 1422.
33.
KantoffP.W., HiganoC.S., SmallE.J.. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.J Natl Cancer Inst.2012; 104(14): 1107–1109.
McGeeD.C., GouldM.K.. Preventing complications of central venous catheterization.N Engl J Med.2003; 348(12): 1123–1133.
37.
BeerT.M., BernsteinG.T., CormanJ.M.. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.Clin Cancer Res.2011; 17(13): 4558–4567.
38.
McNeelD.G., LinD.W., GardnerT.. Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).J Clin Oncol (ASCO Annual Meeting Abstracts).2012; 30(suppl): 4650.
39.
SimsR.B., WenerM.H., dela RosaC.P.. Increased gamma globulin following immunotherapy with sipuleucel-T is associated with antigen-specific antibody responses.Blood. (ASH Annual Meeting Abstracts).2010; 116: 1738.
40.
MadanR.A., GulleyJ.L., FojoT.. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.Oncologist.2010; 15(9): 969–975.
41.
GulleyJ.L., DrakeC.G.. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.Clin Cancer Res.2011; 17(12): 3884–3891.
42.
SmallE.J., HiganoC.S., KantoffP.W.. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): results from three randomized phase III trials.J Clin Oncol (ASCO Annual Meeting Abstracts).2011; 29(suppl): 4661.
43.
ChodakG., SchellhammerP.F., WhitmoreJ.B.. Overall survival (OS) benefit with sipuleucel-T by baseline PSA: an exploratory analysis from the phase III IMPACT trial.J Clin Oncol (ASCO Annual Meeting Abstracts).2012; 30(suppl): 4648.
44.
SheikhN.A., SmallE.J., QuinnD.I.. Sipuleucel-T product characterization across different disease states of prostate cancer.J Clin Oncol (ASCO Annual Meeting Abstracts).2012; 30(suppl 5): 42.
45.
Aragon-ChingJ.B., WilliamsK.M., GulleyJ.L.. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.Front Biosci.2007; 12: 4957–4971.
46.
KandaN., WatanabeS.. Ketoconazole suppresses interleukin-4 plus anti-CD40–induced IgE class switching in surface IgE negative B cells from patients with atopic dermatitis.J Invest Dermatol.2002; 119(3): 590–599.
47.
BeetensJ.R., LootsW., SomersY.. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo.Biochem Pharmacol.1986; 35(6): 883–891.
48.
BaroniA., RuoccoV., De PaolisP.. Ketoconazole inhibits lipopolysaccharide-induced activation of the nitric oxide synthase gene in the murine macrophage cell line J774.Arch Dermatol Res.1999; 291(1): 54–58.
49.
DawsonN.A., PessisD.A., McNeelD.G.. Patients treated with sipuleucel-T who had prior docetaxel had positive immune responses and survival benefit. Presented at the 2011 European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden.Eur J Cancer.2011; 47(suppl 1): S487–S488. Poster 7012.
50.
MercaderM., BodnerB.K., MoserM.T.. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.Proc Natl Acad Sci U S A.2001; 98(25): 14565–14570.
51.
DrakeC.G., DoodyA.D., MihalyoM.A.. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.Cancer Cell.2005; 7(3): 239–249.
52.
GannonP.O., PoissonA.O., DelvoyeN.. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.J Immunol Methods.2009; 348(1-2): 9–17.
53.
SutherlandJ.S., GoldbergG.L., HammettM.V.. Activation of thymic regeneration in mice and humans following androgen blockade.J Immunol.2005; 175(4): 2741–2753.
54.
KohY.T., GrayA., HigginsS.A.. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.Prostate.2009; 69(6): 571–584.
55.
MadanR.A., GulleyJ.L., SchlomJ.. Analysis of overall survival in patients with nonetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.Clin Cancer Res.2008; 14(14): 4526–4531.
56.
FongL., WeinbergV.K., ChanS.E.. Neoadjuvant sipuleucel-T in localized prostate cancer: effects on immune cells within the prostate tumor microenvironment.J Clin Oncol (ASCO Annual Meeting Abstracts).2012; 30(suppl): 2564.
57.
FinkelsteinS.E., TimmermanR., McBrideW.H.. The confluence of stereotactic ablative radiotherapy and tumor immunology.Clin Dev Immunol.2011; 2011: 439752.
58.
BrodeS., CookeA.. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide.Crit Rev Immunol.2008; 28(2): 109–126.
59.
FarsaciB., HigginsJ.P., HodgeJ.W.. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.Int J Cancer.2012; 130(8): 1948–1959.
60.
MirzaN., FishmanM., FrickeI.. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.Cancer Res.2006; 66(18): 9299–9307.
61.
NagarajS., SchrumA.G., ChoH.I.. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.J Immunol.2010; 184(6): 3106–3116.
62.
HerberD.L., CaoW., NefedovaY.. Lipid accumulation and dendritic cell dysfunction in cancer.Nat Med.2010; 16(8): 880–886.
63.
BogunovicD., ManchesO., GodefroyE.. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity.Cancer Res.2011; 71(16): 5467–5476.
64.
WeberJ.. Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade.Semin Oncol.2010; 37(5): 430–439.
65.
PeethambaramP.P., MeliskoM.E., RinnK.J.. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.Clin Cancer Res.2009; 15(18): 5937–5944.
66.
ParkJ.W., MeliskoM.E., EssermanL.J.. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER2 overexpressing breast cancer.J Clin Oncol.2007; 25(24): 3680–3687.
67.
SwietachP., HulikovaA., Vaughan-JonesR.D., HarrisA.L.. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation.Oncogene.2010; 29(50): 6509–6521.
68.
StillebroerA.B., MuldersP.F., BoermanO.C.. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.Eur Urol.2010; 58(1): 75–83.
69.
FinkelsteinS.E., FishmanM.. Clinical opportunities in combining immunotherapy with radiation therapy.Front Oncol.2012; 2: 169. Epub 2012 November 26.
